Epcoritamab-CAR T Cells for Large B-cell Lymphomas

This study is looking into a new way to treat certain types of lymphoma, including Diffuse Large B-cell Lymphoma, using a drug called epcoritamab before or after CAR T-cell therapy. CAR T-cell therapy is a type of treatment where your own immune cells are specially trained to fight cancer. The study wants to see if giving epcoritamab first can help make CAR T-cell therapy more effective, and if epcoritamab can help treat any remaining lymphoma after CAR T-cell therapy. The study is open to adults aged 18 and older who have these types of lymphoma. The main goal is to see how many people who receive epcoritamab can then successfully receive CAR T-cell infusion. The current status of this study is unclear, and it plans to enroll about 31 participants.

Study design: This is an interventional study, meaning participants will receive a specific treatment. It is designed to enroll about 31 participants.
What's involved: Participants will receive subcutaneous injections of epcoritamab at different doses on specific days (Day 1, Day 8, and Day 15 onward of the first cycle).
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint measures the occurrence of CAR T-cell infusion from the start of epcoritamab treatment until the CAR T-cell infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Recruiting

PHASE2Ages 18+InterventionalTreatment

Abramson Cancer Center at Penn Medicine

~31 participants

Updated 2026-05-27 on ClinicalTrials.gov

What's tested:Epcoritamab

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Occurrence of CAR T cell infusion among subjects who receive epcoritamab and undergo leukapheresis

Measured over Start of epcoritamab to CAR T-cell infusion

Conditions

Lymphoma, Non-Hodgkin

Relapsed Diffuse Large B Cell Lymphoma

Refractory Diffuse Large B-cell Lymphoma

High-grade B-cell Lymphoma

Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

NCT06458439

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Elise Chong, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center at the University of Pennsylvania

Who to contact

Brittany Koch

[email protected]

215-776-5548

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age \> 18 years

Subject must be able and willing to provide informed consent. In the case where the patient is incapacitated or not otherwise capable, a legally authorized representative (or decision maker when there is not an advanced directive in place) must be willing to provide informed consent on behalf of the patient.

Able to comply with the study protocol, in the investigator's judgment

ECOG PS of 0 - 2

Pathology report confirming eligible diagnosis

Documented CD20+ tumor cells on most recent biopsy

Patients will have failed to respond to frontline standard of care therapy containing an anthracycline and anti-CD20 antibody

Patients will be eligible and consent to be treated with a "commercially available" anti-CD19, 4-1BB, CD3zeta CAR-T cell therapy or anti-CD19, CD28, CD3zeta CAR T cell therapy (for example, tisagenlecleucel, lisocabtagene maraleucel, or axicabtagene maraleucel)

Patients must have a PET/CT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesions or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \[CT\] scan with FDG-uptake ≥ liver)

Adequate laboratory studies

Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator

Ability and willingness to take proper contraceptive precautions

Exclusion

Inability or unwillingness of the patient or legally authorized representative (or decision-maker when there is not an advanced directive in place) to provide informed consent.

Prior solid organ transplantation

Primary central nervous system (CNS) lymphoma or active secondary CNS involvement by lymphoma at screening as confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan (brain) or, if clinically indicated, by lumbar puncture.

Systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents). However, the following are permitted:

Known past or current malignancy, other than inclusion diagnoses, except for:

Known clinically significant cardiovascular disease

Patients with the following active infection(s) could have increased risks for toxicity if treated with bispecific antibody therapy, thus patient will be excluded if:

Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major documented infection requiring treatment with IV antibiotics or hospitalization within 2 weeks of enrollment. Empiric or prophylactic antibiotics administered during neutropenia or neutropenic fever without microbiologic evidence of infection do not exclude patients.

Clinically significant pulmonary disease (e.g., bronchospasm and/or obstructive pulmonary disease) that requires chronic oxygen or corticosteroid use \> 20 mg mg/day prednisone or equivalent

Uncontrolled seizure disorder

Exposure to live or live attenuated vaccine within 4 weeks prior to signing ICF

Pregnancy or breast feeding

Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

What this trial measures

Occurrence of CAR T cell infusion among subjects who receive epcoritamab and undergo leukapheresisStart of epcoritamab to CAR T-cell infusion
Whether participants receive CAR T-cell infusion (yes/no)

Trialytics